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Abstract Activins and transforming growth factor (TGF)-βs,
members of the TGF-β superfamily, affect numerous physi-
ological processes, including apoptosis, in a variety of organs
and tissues. Apoptotic functions of TGF-βs, in contrast to
those of the activins, are well documented in the developing
and adult nervous system. TGF-βs operate in a context-
dependent manner and cooperate with other cytokines in the
regulation of apoptosis. In this study, we show, for the first
time, an apoptotic function of ActivinA in the nervous system,
i.e. in oligodendroglial progenitor cells. Using the oligoden-
droglial cell line OLI-neu, we show that ActivinA acts
autonomously, without cooperating with TGF-β. In contrast
to the mechanism of TGF-β-mediated apoptosis involving
Bcl-xl down-regulation, Bcl-xl in ActivinA-induced apoptosis
is classically sequestered by the BH3-only protein Puma.
Puma expression is controlled by the transcription factor p53
as demonstrated by experiments with the p53 inhibitor
Pifithrin-α. Furthermore, in the apoptotic TGF-β pathway,
caspase-3 is activated, whereas in the apoptotic ActivinA
pathway, apoptosis-inducing factor is released to trigger DNA
fragmentation. These data suggest that TGF-β and ActivinA
induce apoptosis in oligodendrocytes by different apoptotic
pathways.
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Introduction
Apoptosis plays a significant role in shaping tissues and
organs during development by utilising many different
intracellular signalling pathways leading to the ultimate
demise of the cell. The mitochondrial apoptotic pathway is
regulated by members of the Bcl-2 family comprising pro-
apoptotic and anti-apoptotic proteins (Gross et al. 1999;
Orrenius 2004). Classically, anti-apoptotic proteins such as
Bcl-2, Bcl-xl and Mcl-1 protect mitochondrial integrity,
whereas pro-apoptotic members promote the release of
apoptogenic proteins such as cytochrome C and apoptosis-
inducing factor (AIF) from the mitochondria (Krantic et al.
2007; Orrenius 2004). Pro-apoptotic proteins are further
divided into the BH3-only proteins and the multidomain
effectors Bax and Bak. BH3-only proteins are recognised as
essential initiators of apoptosis because they act as death
ligands to activate the pro-apoptotic effectors Bax and Bak
or to inactivate anti-apoptotic members (Krantic et al. 2007;
Orrenius 2004). Expression of some BH3-only proteins,
including Puma, is promoted by the tumor suppressor p53
(Chipuk and Green 2006).
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Caspases represent initiators and executioners of the
classical apoptotic pathway. Initiator caspases are activated
via extrinsic or intrinsic apoptotic signals to cleave other
caspases and/or diverse effectors leading to apoptotic
changes such as DNA fragmentation and cleavage of
various intracellular substrates (Degterev et al. 2003;
Krantic et al. 2007; Orrenius 2004; Wang 2000). AIF is a
mediator of executioner caspase-independent apoptosis.
Upon mitochondrial permeabilisation, AIF translocates
from the mitochondria to the nucleus. In the nucleus, an
AIF-containing complex triggers large-scale DNA fragmen-
tation (Krantic et al. 2007; Modjtahedi et al. 2006).
The transforming growth factor (TGF)-β superfamily
plays key roles in development and ontogenetic cell death.
The family comprises, amongst other TGF-βs, bone
morphogenetic proteins (BMPs), Activins and related
proteins. TGF-βs act in context depending on the type of
cell, its stage of differentiation and cooperating cytokines/
molecules (Böttner et al. 2000; Sanchez-Capelo 2005;
Schuster and Krieglstein 2002). Activins are important
apoptotic players but have been described so far only in
non-neural systems in adults, e.g. in the immune system, in
the homeostasis of tissues and in tumorigenesis by way of
various apoptotic pathways such as the Bcl-2 family and
the caspase cascade. In neural systems, activins have been
shown to promote survival rather than apoptosis (W. Chen
et al. 2000; Y.G. Chen et al. 2002, 2006). TGF-βs are also
involved in developmental and neuronal apoptosis and
cooperate with other secreted cytokines such as BMPs or
TNF-α (Böttner et al. 2000; Duenker and Krieglstein 2000,
2002, 2003; Duenker et al. 2002a, b; Franke et al. 2006;
Sanchez-Capelo 2005; Schuster et al. 2003; Schuster and
Krieglstein 2002; Unsicker and Strelau 2000). The impor-
tance of TGF-βs during neural ontogenetic cell death was
first shown in chicken, where apoptosis is reduced in various
neuron populations by immunoneutralisation of endogenous
TGF-βs (Krieglstein et al. 2000). In retina cultures, TGF-βs
mediate apoptosis by down-regulation of Bcl-xl protein
(Schuster et al. 2002b). In the oligodendroglial cell line
OLI-neu, TGF-β1-induced apoptosis is accompanied by
down-regulation of caspases and Bcl-xl protein (Schuster
et al. 2003).
In this study, we have analysed apoptotic TGF-β
signalling with regard to possible cooperating factors.
Analysis of oligodendroglial progenitor cells has shown,
for the first time, that ActivinA alone is capable of
mediating apoptosis in the nervous system. Therefore,
ActivinA and TGF-β1 induce apoptosis without coopera-
tion and by functioning in two different pathways. Previous
studies of the TGF-β-responsive OLI-neu cells have
demonstrated that TGF-β mediates DNA fragmentation
through executioner caspases (Schuster et al. 2002a, 2003).
ActivinA, as shown here, induces DNA fragmentation
through AIF translocation from the mitochondria to the
nucleus in an executioner-caspase-independent manner. The
release of the various mediators of DNA fragmentation is
the result of different regulation pathways on the mito-
chondria. In TGF-β-induced apoptosis, Bcl-xl protein is
down-regulated (Schuster et al. 2002a), whereas in Acti-
vinA-induced apoptosis, the amounts of Bcl-xl protein are
unaffected, but Bcl-xl is sequestered through the BH3-only
protein Puma.
Materials and methods
Cell culture and culture conditions
Murine OLI-neu cells were cultured on poly-L-lysine
(PLL)-coated dishes (Nunc) in Dulbecco’s modified Eagle’s
medium with 1% horse serum, penicillin-streptomycin-
neomycin (PSN), N2-supplement (GIBCO), 400 ng/ml L-
thyroxine and 340 ng/ml tri-iodo-L-thyronine (Sigma
Aldrich). Cultured cells were treated with either 5 ng/ml
TGF-β1 or 50 ng/ml ActivinA (both: Peprotech) in serum-
reduced media (0.2% horse serum) without N2-supplement
and PSN. Inhibitors were added 2 h prior to the factors. The
pan-caspase inhibitor Z-VAD-FMK (final concentration:
50 µM) and Pifithrin-α (PFT; final concentration: 20 nM)
were purchased from Calbiochem/Merck Biosciences. The
Alk-4/5/7 inhibitor SB 431542 was from Tocris, Germany,
and was used at a concentration of 10 µM. Primary
oligodendroglial cells were prepared as described by
Schuster et al. (2002a).
RNA interference
The short interfering RNA (siRNA) constructs were
designed with the RNAi pSuper.neo vector system (Oli-
goengine, USA) according to the manufacturer’s guidelines
to interfere with the expression of AIF, the AIF siRNA
sense sequence being 5′-ATGCAGAACTCCAAGCACG-
3′. Cells were transfected with the siRNA vectors by using
Fugene6 in accordance with the manufacturer’s guidelines
at a ratio of 3:2 (Roche Diagnostics). After 3 days of
incubation, cells were treated with cytokines as indicated.
Luciferase assays
Cells (3×104) were seeded in a PLL-coated 48-well plate.
After 16 h of culture, the Smad-binding element (SBE)-
luciferase reporter construct (Jonk et al. 1998) was trans-
fected together with a β-GAL4 control construct by using
Fugene6 (Roche Diagnostics) according to the manufac-
turer’s guidelines at a ratio of 3:2. After 16 h of incubation,
samples were treated with the cytokines and then harvested
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in lysis buffer to measure the luciferase activity and the β-
Gal activity with a luminometer (Lumat LB 9507, Berthold)
by means of the Tropix Assay Kit of Nalgene (Bedford,
Mass., USA) according to the manufacturer’s guidelines.
Measurement of β-Gal activity served as a loading control
to determine equal transfection rates. The luciferase activity
of each sample was normalised to β-Gal activity.
The MLEC/PAI-luciferase assay was carried out accord-
ing to Lacmann et al. (2007)
Immunofluorescence
Cells (2×105) were seeded onto PLL-coated 12-mm glass
coverslips. Treated cells were fixed in 4% paraformalde-
hyde in phosphate-buffered saline (PFA/PBS) for 20 min
and permeabilised with 0.1% Triton X-100 for 10 min at
room temperature. Following several washing steps, block-
ing was performed with 5% bovine serum albumin in PBS
for 1 h. Smad1/2/3 antibody (Santa Cruz) or AIF antibody
(Chemicon) were detected by Cy3-conjugated secondary
antibodies (Jackson ImmunoResearch Europe). Samples
were mounted in Fluoromount-G mounting solution
(Southern Biotechnology) containing 4,6-diamidino-2-phe-
nylindole (DAPI). Whole cell analysis was performed by
using a Nikon Eclipse E600 microscope with an Axio-
CamHR camera (Carl Zeiss). Images were examined with a
Nikon PLAN APO 40x/0.95 lens at room temperature.
Fluorochromes were visualised with filter sets for DAPI
(364/454 nm) and Cy3 (552/570 nm).
Caspase activity assays
Samples were lysed with lysis buffer (10 mM TRIS-HCl,
10 mM NaH2PO4/NaHPO4, pH 7.5, 130 mM NaCl, 1%
Triton X-100). Protein amounts were measured by using the
Bradford assay. Caspase-2 (z-VDVAD-AFC) and caspase-9
(Ac-LEHD-AFC; Calbiochem), and caspase-8 (Ac-IETD-
AFC) and caspase-3 (Ac-DEVD-AMC; BD Bioscience
Europe) activity assays were employed according to the
manufacturer’s guidelines and incubated together with
20 µg protein for 6 h at 37°C in an opaque 96-well plate
(Greiner Labortechnik). Fluorometric probes were mea-
sured in the FLX800 Fluorescence Reader (BioTek Instru-
ments) with suitable filters (AFC-fluorophores: excitation
400 nm, emission 505 nm; AMC-fluorophores: excitation
380 nm, emission 430–460 nm).
Western blotting
Total protein extracts were isolated with cell lysis buffer
[10 mM TRIS-HCl, pH 7.4, 1.5 mMMgCl2, 0.5% Nonident
P40, complete protease inhibitor mix (Roche Diagnostics)].
Following sonication (3×10 s), samples were centrifuged
at 13,000 rpm for 10 min. Subcellular fractionation of
proteins was performed according to the manufacturer’s
guidelines by using the ProteoExtract® Subcellular Pro-
teome Extraction Kit from Calbiochem. Protein samples
were measured with the Bradford assay (Bio-Rad Labora-
tories). Equal amounts of protein were prepared with
NuPage sample buffer (Invitrogen) and separated by SDS-
gel-electrophoresis (BioRad Lab). Proteins were transferred
onto nitrocellulose membrane (BioCat), blocked in 5%
milk/TRIS-buffered saline with Triton X-100 for 1 h and
probed with primary antibodies [Puma, Bcl-xl, CoxIV and
Bax antibodies (Cell Signaling Tech), p53 (FL-393; Santa
Cruz), AIF and Fractin antibodies (Chemicon Europe)]. As
loading controls, D-glyceraldehyde-3-phosphate dehydro-
genase (Gapdh) protein was detected by Gapdh antibody
(Acris) and Histon1 by H1 (4112) antibody (kind gift of D.
Doenecke, Department of Molecular Biology, University of
Göttingen, Germany). Primary antibodies were detected by
horseradish-peroxide-conjugated secondary antibodies
(Jackson ImmunoResearch Europe) and immunoreactive
signals were developed by chemiluminescence according to
the manufacturer’s protocol (Millipore).
Immunoprecipitation
Treated cells (2×106) were harvested and resuspended in
cell lysis buffer [50 mM TRIS pH 7.5, 500 mM NaCl, 1%
Nonident P40, complete protease inhibitor mix (Roche
Diagnostics)]. After sonication (3×10 s), samples were
centrifuged at 13,000 rpm for 10 min and 50 µl ProteinA
sepharose 4 Fast Flow beads (50% slurry; Amersham
Bioscience Europe) pre-cleared the cell lysates. Equal
protein amounts were determined by the Bradford assay.
IP antibodies (1–2 µg) were used for antigen coupling.
Bcl-xl was purchased from Cell Signaling Tech. Precipita-
tion of immune complexes was carried out by adding 20 µl
ProteinA sepharose. The immune complexes were washed
and mixed with 2xNuPage sample buffer (Invitrogen) to
analyse the supernatants by SDS-gel-electrophoresis as
described (above).
TGF-β release assay
Specific quantification of released TGF-β was as described
elsewhere (Krieglstein et al. 2000).
Flow cytometry
Cells (2×105) were trypsinised, washed in PBS, and fixed
in 70% ethanol at -20°C overnight. Samples were washed
in PBS before being staining with propidium iodide
solution (100 µg/ml propidium iodide, 100 µg/ml RNase
in PBS) for 30 min at 37°C. Fluorescence-activated cell
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sorting (FACS) samples were counted with a FACScan
flow cytometer and analysed with CellQuest software
(Becton Dickinson). The percentage of cells present in the
sub-G1 peak, representing apoptotic cells, was calculated
after exclusion of cell doublets.
Detection of cell death by TUNEL technology
Cells (2×105) were cultured on PLL-coated 12-mm glass
slides, treated and fixed in 4% PFA/PBS for 60 min.
Fragmented nuclei were detected with the In Situ Cell Death
Detection Kit, TMR red according to the manufacturer’s
guidelines (Roche Diagnostics). Samples were mounted in
DAPI/Fluoromount-G (Southern Biotech) staining solution.
Whole cell analysis was performed by using a Nikon
Eclipse E600 microscope with an AxioCamHR camera
(Carl Zeiss). To quantify the number of dead cells, red
fluorescence (filter: 552/570 nm) was determined in
relation to DAPI-stained nuclei.
Densitometric measurement and statistical analysis
Densitometric quantification of signals was carried out with
the AlphaEaseFC program. Measurements of experimental
bands were compared with loading control, by calculating
the relative values (±SEM). Statistical analysis of the data
was performed with Prism4 GraphPad Software using
Student’s t-test.
Results
ActivinA induces apoptosis in oligodendroglial progenitor
cells
TGF-β is known as a contextually acting molecule that
cooperates with other cytokines, including TNF-α and
BMPs, to induce apoptosis (Franke et al. 2006; Schuster et
al. 2003). In the present study, we show that another
cytokine of the TGF-β superfamily, ActivinA, also induces
apoptosis in oligodendroglial progenitor cells (Fig. 1a,b).
ActivinA mediated apoptosis as analysed by flow
cytometry and the counting of apoptotic nuclei (sub-G1
peak). A dose of 50 ng/ml ActivinA proved to be an
optimal apoptotic condition (Fig. 1a). TGF-β1 (5 ng/ml)
served as positive apoptotic control. To test whether
ActivinA and TGF-β1 cooperated in their capacity to
induce apoptosis, we co-treated OLI-neu cells with 5 ng/ml
TGF-β1 and 50 ng/ml ActivinA. This combination resulted
in the same apoptosis rate as treatment with TGF-β1 alone,
excluding a possible cooperation between TGF-β1 and
ActivinA (Fig. 1a). Further, TUNEL staining showed a
significant increase of fragmented DNA following Acti-
vinA treatment (Fig. 1b). TGF-β-mediated apoptosis
seemed to be more potent than ActivinA-mediated apopto-
sis, as seen in flow cytometry and in TUNEL staining
(Fig. 1a,b). To confirm that ActivinA induced apoptosis in
oligodendrocytes, we performed TUNEL staining in pri-
mary oligodendroglial cultures (Fig. 1e). By counting
TUNEL-positive nuclei in relation to DAPI-positive nuclei,
we showed that ActivinA also significantly induced
fragmented DNA in primary oligodendroglial cultures.
To exclude the possibility that apoptosis is an effect of
ActivinA-induced TGF-β release, we performed TGF-β
release assays. OLI-neu cells were pre-treated with the
neutralising antibody against TGF-β1/2/3 to absorb all
released TGF-β isoforms. After additional ActivinA treat-
ment (20 h), cells were analysed by flow cytometry,
apoptotic nuclei being counted. As shown in Fig. 1c, in
spite of co-treatment with neutralising antibodies, ActivinA
induced DNA fragmentation. We additionally determined
possible TGF-β release by using a highly specific and
sensitive TGF-β bioassay, the MLEC/PAI-luciferase assay
(Lacmann et al. 2007). As seen in Fig. 1d, after ActivinA
treatment (12 h), no increased amounts of TGF-β were
detectable in the cell culture supernatants. Together, these
results indicate that two independent cytokine-induced
apoptotic pathways exist in the same cell type.
The signal transduction of the TGF-β superfamily is
mediated through Smad proteins, which translocate into the
nucleus (Derynck and Zhang 2003). Using a Smad-binding
element (SBE)-luciferase reporter assay, we demonstrated
that the Smad cascade was significantly activated by
ActivinA and was blocked following co-treatment with
the Alk4/5/7 inhibitor SB421542 (Fig. 2a). Immunocyto-
chemistry experiments with a Smad1/2/3 antibody con-
firmed Smad activation by showing Smad translocation into
the nucleus after ActivinA treatment (2 h; Fig. 2b).
ActivinA leads to an AIF-mediated DNA fragmentation,
whereas TGF-β-mediated apoptosis occurs via executioner
caspases
To characterise the apoptotic pathway in ActivinA-induced
cell death, we attempted to identify the caspase cascade that
might be involved in the ActivinA network. In TGF-β-
induced apoptosis, initiator and executioner caspases are
activated (Schuster et al. 2002a, 2003). To test whether
caspases per se were involved in apoptotic processes after
ActivinA treatment, we inhibited all caspases by an
irreversible broad-spectrum caspase inhibitor (Z-VAD-
FMK). After pre-treatment with the pan-caspase inhibitor,
we added ActivinA and analysed apoptotic nuclei by flow
cytometry. TGF-β1-treated samples served as a positive
control. As shown in Fig. 3a, the apoptotic cell population
was reduced after co-treatment with ActivinA and pan-
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caspase inhibitor revealing that ActivinA-induced apoptosis
was caspase-dependent. To identify which specific caspases
were involved in the ActivinA-induced pathway, we
performed caspase activity assays for initiator caspase-2
and caspase-8, for mitochondrial caspase-9 and for execu-
tioner caspase-3 (Fig. 3b-e). After treatment with ActivinA
or TGF-β1 for various time periods (8–20 h), cells were
harvested and proteins were used for fluorometric activity
assays. Initiator caspase-2 and caspase-8 were significantly
activated following ActivinA or TGF-β1 treatment
(Fig. 3b,c). Mitochondrial caspase-9 and executioner
caspase-3 were only significantly involved in TGF-β1-
induced samples (Fig. 3d,e). From these experiments, we
conclude that the classical caspase cascade involving
caspase-3 to induce DNA fragmentation is only activated
in TGF-β-mediated apoptosis. In the ActivinA pathway,
another DNA-fragmentation-inducing molecule must be
involved.
Fig. 1 ActivinA induces apoptosis in oligodendrocytes, autonomously
of TGF-β. a ActivinA (ActA)-mediated DNA fragmentation. OLI-neu
cells were treated with ActivinA at various concentrations for 20 h.
TGF-β1-treated cells served as an apoptotic control. Cells were
harvested and fixed in 70% ethanol and nuclei were stained with
propidium iodide for flow cytometry. The intensity of the stained
nuclei showed the stage of the cell. The sub-G1 peak (DNA<n2)
represented apoptotic nuclei. Values are means ±SEM of three separate
experiments. ***Statistically significant difference at P<0.001, calcu-
lated by Student’s t-test. b OLI-neu cells were seeded on glass slides
and treated with ActivinA (50 ng/ml) for 20 h. Fixed cells were
prepared for staining of fragmented DNA by enzymatic fluorescence
labelling. Counts of fragmented DNA were compared with phase-
contrast images. c ActivinA (ActA) acts autonomously of TGF-β. OLI-
neu cells were pre-treated with neutralising TGF-β1/2/3 antibody and
ActivinA (50 ng/ml) was added for 20 h. Apoptotic cells were
analysed by flow cytometry as in a. d ActivinA does not induce TGF-
β release. OLI-neu cells were cultured and treated with 50 ng/ml
ActivinA for 12 h. Supernatants were quantified with the MLEC/PAI-
luciferase assay. Data are given as amounts of TGF-β release in the
supernatant, as means±SEM of two separate experiments, each with
two replicates (RLU relative light units). Statistical significance was
tested with Student’s t-test. e DNA fragmentation in primary cultures.
Primary oligodendroglial cells were seeded on glass slides and treated
with ActivinA (50 ng/ml) for 20 h. Fixed cells were prepared for
staining of fragmented DNA by enzymatic fluorescence labelling with
subsequent DAPI staining. Positive-fragmented cells were counted in
relation to DAPI staining and the percentage of apoptotic cells was
calculated. Values are given as means ±SEM of three separate
experiments, counting 3000 cells. ***Statistcially significant at
P<0.001, calculated by Student’s t-test
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Several studies have shown that AIF is a mediator of
caspase-independent cell death or, more exactly, of execu-
tioner-caspase-independent cell death (Krantic et al. 2007).
To analyse whether AIF is involved in ActivinA-induced
DNA fragmentation, we performed AIF release assays.
Isolated mitochondrial and nuclear protein fractions were
analysed by Western blot and showed a 3.6-fold AIF
translocation into the nucleus only after ActivinA treatment
(Fig. 4a). In TGF-β-treated samples, no AIF translocation
into the nucleus could be observed. Immunocytochemical
experiments validated the AIF translocation into the
nucleus (Fig. 4b). In ActivinA-induced OLI-neu cells
(16 h), we detected strong nuclear AIF staining if the
nuclei were condensed or fragmented, as shown by DAPI
staining. In control cells, the AIF staining appeared
granular in the cytosol. In primary oligodendroglial
cultures, nuclear AIF staining was also observed after
ActivinA treatment (Fig. 4d).
To delimit ActivinA-induced apoptosis from TGF-β-
induced apoptosis, we silenced AIF expression with a green
fluorescent protein (GFP)-tagged siAIF expression vector
system. After transfection of OLI-neu cells with the GFP/
siAIF vector for 3 days, we analysed AIF silencing by
Western blot (Fig. 4c). AIF expression was reduced to
approximately one-third, in agreement with the AIF knock-
down Harlequin mouse strain (Modjtahedi et al. 2006). To
verify the AIF dependence in apoptosis, GFP/siAIF-trans-
fected OLI-neu cells (3 days incubation) were treated either
with ActivinA or with TGF-β1 for 20 h and DNA
fragmentation was analysed by TUNEL staining (Fig. 4e).
The AIF knock-down could only block ActivinA-induced
DNA fragmentation, whereas TGF-β1-mediated DNA
fragmentation also occurred, despite AIF knock-down.
These results show that ActivinA induces apoptosis via
mitochondrial AIF release, whereas TGF-β activates
executioner caspases to induce DNA fragmentation.
ActivinA induces Bcl-xl sequestering by Puma to release
AIF, whereas TGF-β reduces Bcl-xl protein amounts
We assumed that different regulatory mechanisms were
acting on mitochondria to trigger DNA fragmentation by
AIF or caspase-3. Therefore, we investigated the regulation
of Bcl-xl. In TGF-β1-induced apoptosis, Bcl-xl protein
amounts are decreased (Schuster et al. 2002a). In contrast,
Bcl-xl protein amounts in ActivinA-treated cells were
unaltered (Fig. 5a). Because of this important difference
in Bcl-2 family regulation, we investigated other Bcl-2
family members known to be involved in mitochondrial
events. Thus, we analysed BH3-only proteins and discov-
ered an increase in Puma expression after ActivinA
treatment (Fig. 5b). In primary oligodendroglial cultures,
we also detected Puma activation after ActivinA treatment
(Fig. 5c). Compared with ActivinA, TGF-β1 was not able
to mediate an increase in Puma expression (Fig. 5b). The
tumor suppressor p53 is the most important transcription
factor of Puma (Nakano and Vousden 2001). We used the
p53 inhibitor PFT to explore p53 function in ActivinA-
induced apoptosis. OLI-neu cells were pre-treated with PFT
and either ActivinA or TGF-β1 was added for 20 h. Cells
were harvested and prepared for flow cytometry, apoptotic
nuclei being counted (Fig. 5d). PFT significantly prevented
ActivinA-induced, but not TGF-β-induced apoptosis. To
analyse the effect of PFT on ActivinA-mediated AIF
translocation into the nucleus, we isolated mitochondrial
and nuclear protein phases from treated cells and performed
Fig. 2 a Analysis of Smad activation in ActivinA-mediated apoptosis.
OLI-neu cells were cultured and transfected with an SBE-luciferase
construct for 16 h. SB431542 was pre-incubated for 2 h, and 50 ng/ml
ActivinA was added for 12 h. After cell lysis, Smad activation was
monitored by measurement of luciferase expression. Luciferase
activity was compared with β-Gal activity to calculate relative values.
Values are given as means ±SEM of two separate experiments, each
with two replicates; **P<0.01 (Student’s t-test). b Immunofluores-
cence staining of Smad-1/2/3 together with DAPI staining. OLI-neu
cells were treated with ActivinA for 2 h. TGF-β1 served as a positive
control. Nuclear Smad staining occurred in ActivinA-treated and in
TGF-β-treated samples. Bar 8 µm
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Western blots with an AIF antibody. As shown in Fig. 5e,
PFT inhibited the ActivinA-induced AIF translocation.
These results clearly indicate that ActivinA-mediated AIF
translocation depends on p53.
The regulatory context, including Puma, nuclear and
cytosolic p53 and other Bcl-2 family members, can vary
and is dependent on cell type (Chipuk and Green 2006;
Mihara et al. 2003). To ascertain the various possibilities,
we decided to analyse whether Puma expression was
dependent on nuclear p53 in our OLI-neu model. For this
purpose, OLI-neu cells were pre-treated with PFT and
ActivinA was added for 8 h. TGF-β1-treated samples
served as a negative control. As shown in Fig. 6a, PFT
reduced Puma activation in ActivinA-treated cells revealing
a role for p53 as a nuclear factor to activate Puma
expression. Puma is known to interact only with pro-
survival proteins such as Bcl-xl and Bcl-2 (L. Chen et al.
2005) and, therefore, we investigated these two possible
binding partners for Puma. Immunoprecipitations showed
that Bcl-xl served as interaction partner for Puma following
ActivinA treatment in our cell model (Fig. 6b). In contrast,
Puma failed to interact with Bcl-xl in TGF-β-induced
apoptosis (Fig. 6b). Further, we could not detect any
binding of Bcl-2 to Puma, neither in TGF-β- nor in
Fig. 3 Analysis of the caspase
cascade in ActivinA (ActA)-in-
duced apoptosis. a OLI-neu
cells were pre-treated with
50 µM of the pan-caspase in-
hibitor Z-VAD-ZMK, and Acti-
vinA (50 ng/ml) or TGF-β1
(5 ng/ml) was added for 20 h.
Percentage of apoptotic cells
(sub-G1 peak, DNA<n2) was
determined by flow cytometry.
Values represent means±SEM
from three separate experiments;
***P<0.001 (Student’s t-test).
b–e OLI-neu cells were treated
with ActivinA (50 ng/ml) or
TGF-β1 (5 ng/ml) at various
time points and lysed; equal
protein amounts were assayed
for the activity of caspase-2 (b),
caspase-8 (c), caspase-3 (d) and
caspase-9 (e). Treated samples
were normalised to control cells.
Values are given as means±SEM
from three separate experiments,
each with two replicates;
*P<0.05, **P<0.01,
***P<0.001
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ActivinA-mediated apoptosis (data not shown). Because of
the PFT-mediated reduction of ActivinA-induced DNA
fragmentation, we analysed whether cytoplasmic p53 could
also interact with Bcl-xl or Bax (Chipuk and Green 2006;
Kuwana et al. 2005; Mihara et al. 2003). Immunoprecipi-
tation experiments excluded Bcl-xl and Bax as p53
interaction partners in OLI-neu cells (data not shown).
The consequence of Bcl-xl sequestering by a BH3-only
protein is the translocation of pro-apoptotic effectors, such
as Bax, to the mitochondria (Gross et al. 1999; Orrenius
2004). As shown in subcellular fragmentations, Bax
translocation to mitochondria was increased after ActivinA
treatment (Fig. 6c). PFT inhibited Bax translocation
showing that Bax activation lay downstream of p53 in the
ActivinA signalling pathway (Fig. 6c).
These data show that apoptosis in oligodendrocytes
occurs through TGF-β and ActivinA, independently of
each other and via different mechanisms. TGF-β mediates
Fig. 4 AIF translocates into the nucleus only after ActivinA
treatment. a Analysis of subcellular localisation of AIF in fractionated
samples after treatment with ActivinA (50 ng/ml) and TGF-β1 (5 ng/ml;
16 or 24 h). Subcellular fractioning was verified by characteristic
markers [CoxIV mitochondrial (mtc) fraction, H1 nuclear (nc) fraction]
as loading control. Measurements of experimental bands were
normalised to loading control. b, d ActivinA (ActA)-induced nuclear
AIF staining. OLI-neu cells (b) or primary oligodendroglial cultures (d)
were treated with 50 ng/ml ActivinA for 16 h. After fixation,
immunofluorescence staining of AIF together with DAPI staining
was performed. Bars 8 µm. c Analysis of AIF silencing. OLI-neu cells
were transfected with green fluorescent protein (GFP)/short interfering
RNA (siRNA) expression vectors for AIF (siAF) or scramble
(Scramble) for 3 days. AIF expression was tested by Western blotting.
D-glyceraldehyde-3-phosphate dehydrogenase (Gapdh) served as
loading control. AIF expression was normalised to Gapdh expression
and compared with the control. e ActivinA (ActA)-induced apoptosis is
dependent on AIF. OLI-neu cells were transfected with GFP/siRNA
expression vectors for AIF or scramble for 3 days. After down-
regulation of AIF expression, ActivinA (50 ng/ml) or TGF-β1 (5 ng/
ml) was added for 20 h. Apoptotic cells were identified by TUNEL
staining. Positive-fragmented cells were counted in relation to GFP-
stained cells and the percentage of apoptotic cells was calculated.
Values are given as means±SEM (three separate experiments counting
3000 cells). **Statistically significant difference at P<0.01, calculated
by Student’s t-test
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apoptosis involving Bcl-xl protein down-regulation to
imbalance anti-apoptotic and pro-apoptotic factors on the
mitochondria; this leads to the activation of executioner
caspases to trigger DNA fragmentation. ActivinA induces
p53-dependent Puma expression to sequester Bcl-xl and to
activate Bax. The Bax-mediated pore formation on the
mitochondria leads to the release of AIF and subsequent
DNA fragmentation.
Discussion
In the present study, we show that TGF-β1 and ActivinA
induce apoptosis in oligodendrocytes. Whereas apoptotic-
acting TGF-βs are well described in ontogenetic cell death
and in the nervous system (Böttner et al. 2000; Duenker
and Krieglstein 2000, 2002, 2003; Duenker et al. 2002a, b;
Krieglstein et al. 2000; Sanchez-Capelo 2005; Schuster and
Krieglstein 2002; Unsicker and Strelau 2000), apoptotic-
acting Activins have so far only been described in non-
neural and adult systems (W. Chen et al. 2000; Y.G. Chen
et al. 2002, 2006). Thus, we present, for the first time,
evidence that ActivinA also induces apoptosis in the
nervous system, especially in oligodendroglial progenitors.
Further analysis with the established oligodendroglial
precursor cell line OLI-neu has excluded cooperative
effects between ActivinA and TGF-β, which is known to
induce apoptosis in this model system (Schuster et al.
2002a). The autonomy of these two cytokine-mediated
pathways is reflected by their different effects on mito-
chondria resulting in separate DNA fragmentation mecha-
nisms. Whereas TGF-β down-regulates Bcl-xl protein
(Schuster et al. 2002a), Bcl-xl is sequestered, in ActivinA-
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Fig. 5 a Analysis of Bcl-xl expression. ActivinA (ActA)-treated
(50 ng/ml) or TGF-β1-treated (5 ng/ml) cells were lysed and prepared
for Western blotting with a Bcl-xl antibody. Gapdh served as loading
control. b, c Puma activation in ActivinA (ActA)-induced cell death in
oligodendrocytes. OLI-neu cells (b) or primary oligodendroglial cells
(c) were treated with ActivinA (50 ng/ml) or TGF-β1 (5 ng/ml) for
various time spans, lysed and prepared for Western blotting with an
antibody against Puma. Gapdh served as loading control. d ActivinA-
induced apoptosis is dependent on p53. OLI-neu cells were pre-treated
with 20 µM p53 inhibitor Pifithrin-α (PFT) and ActivinA (50 ng/ml)
or TGF-β1 (5 ng/ml) was added for 20 h. Percentage of apoptotic cells
(sub-G1 peak) was determined by flow cytometry. Values represent
means±SEM (three separate experiments); **P<0.01 (Student’s t-test).
e AIF translocation is dependent on p53. After a pre-incubation in
20 µM PFT, ActivinA-treated cells (16 h) and non-treated cells were
fractionated into their subcellular components to determine the
subcellular fraction of AIF. AIF expression was normalised to loading
controls of the subcellular fractions [CoxIV mitochondrial (mtc)
fraction, H1 nuclear (nc) fraction]
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Puma that regulates apoptotic pathways by interacting with
anti-apoptotic proteins to release Bax (L. Chen et al. 2005;
Kuwana et al. 2005). Thereby, Puma expression is
dependent on its transcription factor p53 (Nakano and
Vousden 2001). In contrast to TGF-β, ActivinA-induced
apoptosis and Bax translocation are prevented by the p53
inhibitor PFT.
The different DNA fragmentation processes in the
ActivinA and TGF-β pathways confirm two existing
apoptotic pathways in oligodendrocytes. Whereas caspase-
3 is activated in TGF-β-induced apoptosis, AIF triggers
DNA fragmentation in ActivinA-induced apoptosis. AIF
was firstly described as a caspase-independent mediator of
DNA fragmentation, but further studies showed an involve-
ment of caspases such as caspase-2 (Arnould et al. 2003;
Seth et al. 2005). We have demonstrated that ActivinA-
induced apoptosis and AIF release are dependent on
caspases based on results with the pan-caspase inhibitor
Z-VAD-FMK. Caspase-dependent AIF release has also
been shown to be the possible consequence of calpain
inhibition by Z-VAD-FMK, because calpains are important
proteases of AIF cleavage (Modjtahedi et al. 2006). We
have excluded this possibility with calpain activity assays
and specific calpain inhibitors, which have failed to detect
calpain activation in ActivinA-induced apoptosis. Indeed,
caspases play a role in ActivinA-induced DNA fragmenta-
tion and AIF release, but their involvement in the ActivinA
network is not yet fully understood. Caspase-2 and caspase-
8 are activated in both cytokine-mediated pathways, in
contrast to caspase-3. How these same caspases lead to
differences in signalling pathways has, until now, been
unclear. Possibly, p53 involvement, which has been
demonstrated only in the ActivinA pathway, distinguishes
between the two signal branches. Hence, it is shown that
caspase-2 activation mediates a functional connection to
p53 to release AIF, as described in other cell models
(Seth et al. 2005; Vakifahmetoglu et al. 2006).
Further, the way that TGF-β superfamily signalling is
discriminated intracellularly, leading to the different events
of p53-dependent Puma expression (ActivinA) or Bcl-xl
protein down-regulation (TGF-β) is of interest. In OLI-neu
cells, general Smad activation is stimulated by ActivinA
and by TGF-β, but without further clarification of the
diverse TGF-β superfamily regulation regarding combina-
torial interactions, heterodimeric receptors, Smad com-
plexes, receptor-interacting proteins and Smad-interacting
proteins (Derynck and Zhang 2003). Different regulatory
Smads or diverse phosphorylation sites in Smads might
mediate various types of transcriptional regulation. How-
ever, further studies are required to complete our under-
standing of the role of Smads in these apoptotic pathways.
An important question is why the cell possesses two
different apoptotic pathways that are inducible by different
cytokines. In the present study, we have excluded the
possibility of cooperating effects between TGF-β and
ActivinA and have demonstrated that the two pathways
are indeed different with respect to the involved signalling.
Another explanation could be that different cellular stages
occur in primary oligodendroglial cultures and in our
cellular model OLI-neu. In thymocytes, Activin and TGF-
β have been shown to act individually at different
maturation stages (Rosendahl et al. 2003). However, we
clearly demonstrate that OLI-neu cells are responsive to
either TGF-β or ActivinA, at the same time showing
double-responsive cells that might be in a specific matura-
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Fig. 6 Activated Puma sequesters Bcl-xl resulting in Bax transloca-
tion to mitochondria in ActivinA-induced apoptosis. a Nuclear p53
induces Puma expression. OLI-neu cells were pretreated with 20 µM
PFT, and ActivinA (50 ng/ml) or TGF-β1 (5 ng/ml) was added for
8 h. By Western blotting, Puma expression was detected in lysed
samples with a Puma antibody. Gapdh served as loading control. b
Puma sequesters Bcl-xl following ActivinA treatment. For immuno-
precipitation, equal amounts of ActivinA-treated and TGF-β1-treated
proteins (8 h) were tested with Bcl-xl antibody. A rabbit IgG antibody
served as a control for unspecific binding. As shown in an
immunoblot (IB) for Puma protein, the Bcl-xl protein is sequestered
by Puma represented by a 22-kDa band. c Subcellular fractionation
experiments of ActivinA-induced OLI-neu cells for Bax translocation.
Cells were pretreated with PFT and then treated with 50 ng/ml
ActivinA for 8 h. Samples were fractionated into a cytosolic (cyto)
phase and a mitochondrial (mtc) phase and analysed by Western
blotting. Bax translocation to mitochondria was detected by a Bax
antibody. Gapdh served as loading control for the cytosolic fraction
and CoxIV as loading control for the mitochondrial fraction
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mental switch occurs depending on the available cytokines
during development. However, further studies are required
to answer this question.
Thus, our results have revealed the presence of two
different apoptotic pathways in the same cellular context
induced by either ActivinA or TGF-β, both members of the
TGF-β superfamily. Thereby, we have shown, for the first
time, that ActivinA induces apoptosis in neural cells. In our
glial model, ActivinA promotes apoptosis through the
neutralisation of the Bcl-xl function, whereas TGF-β
triggers apoptosis by the down-regulation of the Bcl-xl
protein. These diverging regulation patterns of the same
Bcl-2 family member lead to different DNA fragmentation
mechanisms.
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